Launching the Women’s Cancer Moonshot Anil K. Sood, M.D., Professor Vice Chair, Translational Research Departments of Gynecologic Oncology and Cancer Biology Co-Director, Center for RNAi and Non-Coding RNA Director, Blanton-Davis Ovarian Cancer Research Program
18
Embed
2014 Ovarian Cancer National Conference: Launching the Women's Cancer Moonshot
This document is posted to help you gain knowledge. Please leave a comment to let me know what you think about it! Share it to your friends and learn new things together.
Transcript
Launching the Women’s Cancer Moonshot
Anil K. Sood, M.D., Professor Vice Chair, Translational Research
Departments of Gynecologic Oncology and Cancer Biology Co-Director, Center for RNAi and Non-Coding RNA
Director, Blanton-Davis Ovarian Cancer Research Program
Concept: Make the Impossible…Possible
John F. Kennedy Moon Speech, Rice Stadium September 12, 1962
Strategic Initiative
Cancer Moon Shot Program
Can we systematically harness the full potential of today’s
technology, major conceptual advances and our critical
mass and collaborative networks to more rapidly drive
progress in the field?
Why a Combined Ovarian and Breast Cancer Moonshot?
• Medical Need and Impact
• Deep knowledge and molecular characterization
• Common predisposition factors Common concepts for risk, prevention, screening and
survivorship
• Molecular, biological and clinical commonalities
• Cross pollination
Flagship Projects: THE START
• Will have immediate impact on patient outcomes
• Can be implemented without “new knowledge”
• Broadly applicable across disease
• Engage the community: Faculty, patients and outreach
• Efficiencies offered by Moon Shot Platforms
Germline BRCA-1 and -2 testing (>10% will be positive)
Active Outreach
Screening Prevention
Offer genetic testing to all patients with HGSOC or TNBC
Flagship project 1a: Impacting the Family
Goal: 80% decrease in deaths in
family members over 5 years
Flagship project 1a: Impacting the Family
20-50% of patients will have a defect in the function of BRCA1 or
BRCA2
PARP-inhibitor based therapy
Offer genetic testing to all patients with HGSOC or TNBC
• P53 based approaches – synthetic lethality • Adaptive changes to therapy • Rational combination therapy (e.g., new combinations of kinase
inhibitors, synergistic combinations with PARP inhibitors) • Immune modulation/inflammation as therapy targets • Mechanisms by which stress hormones affect tumor growth
• Survivorship • Identify and validate predictors of long-term survival • Predictors of toxicity
• Collaborating organizations: – M.D. Anderson – Memorial Sloan Kettering – Cedars Sinai Medical Center – Univ. of Iowa – Univ. of Oklahoma – OCNA – Clearity Foundation – Nine Girls Ask
Consortium to Study Long-Term Survivors of Ovarian Cancer (DOD)
• Projects: 1. Molecular predictors 2. Biobehavioral, social, and
demographic features 3. Clinical and surgical factors